PharmaEssentia Taichung Plant Obtains Vietnam GMP, Promotes Market Approval Review for New Drug BESREMi
PharmaEssentia announced that its Taichung plant has passed the Vietnam GMP certification. The company will apply for market approval for its new drug BESREMi in Vietnam.
📋 Article Processing Timeline
- 📰 Published: April 22, 2026 at 20:30
- 🔍 Collected: April 22, 2026 at 21:02 (31 min after Published)
- 🤖 AI Analyzed: April 23, 2026 at 07:57 (10h 54m after Collected)
ASEAN Financial Special Report (Total 300 articles)
Central News
Master the New Southbound Policy, look to the ASEAN economic pulse. CNA's "Southeast Asia Financial Information Network" daily selects multiple financial headlines from Thailand, Vietnam, Indonesia, Malaysia, the Philippines, etc. Whether it's new government policies, industry trends, or investment opportunities, allowing you to instantly grasp key information, understand the market, and seize business opportunities.
(CNA Taipei 22nd) PharmaEssentia stated that its Taichung plant has been certified by the Drug Administration of Vietnam under the Ministry of Health as passing Good Manufacturing Practice (GMP), and has applied for market approval of Ropeginterferon alfa-2b in Vietnam.
PharmaEssentia's Taichung plant has been recognized by the Drug Administration of Vietnam under the Ministry of Health for passing GMP, and the new drug BESREMi developed by the company will apply for market approval in Vietnam for the treatment of Polycythemia Vera.
In addition, PharmaEssentia continues to develop a more diverse product line and strengthen domestic and overseas cooperation, not only discussing planning with major biotechnology parks and hospital incubation centers in Taiwan, but also planning to invest in new drug technologies or products overseas, exploring new aspects for the treatment of other cancers and rare diseases. 1150422
Choose to stand with facts, every sponsorship of yours is the power to protect freedom of the press.
Download the CNA "First-hand News" APP to grasp the latest news instantly.
The text, images, and audio/video on this website may not be reproduced, publicly broadcast, or publicly transmitted and utilized without authorization.
Central News
Master the New Southbound Policy, look to the ASEAN economic pulse. CNA's "Southeast Asia Financial Information Network" daily selects multiple financial headlines from Thailand, Vietnam, Indonesia, Malaysia, the Philippines, etc. Whether it's new government policies, industry trends, or investment opportunities, allowing you to instantly grasp key information, understand the market, and seize business opportunities.
(CNA Taipei 22nd) PharmaEssentia stated that its Taichung plant has been certified by the Drug Administration of Vietnam under the Ministry of Health as passing Good Manufacturing Practice (GMP), and has applied for market approval of Ropeginterferon alfa-2b in Vietnam.
PharmaEssentia's Taichung plant has been recognized by the Drug Administration of Vietnam under the Ministry of Health for passing GMP, and the new drug BESREMi developed by the company will apply for market approval in Vietnam for the treatment of Polycythemia Vera.
In addition, PharmaEssentia continues to develop a more diverse product line and strengthen domestic and overseas cooperation, not only discussing planning with major biotechnology parks and hospital incubation centers in Taiwan, but also planning to invest in new drug technologies or products overseas, exploring new aspects for the treatment of other cancers and rare diseases. 1150422
Choose to stand with facts, every sponsorship of yours is the power to protect freedom of the press.
Download the CNA "First-hand News" APP to grasp the latest news instantly.
The text, images, and audio/video on this website may not be reproduced, publicly broadcast, or publicly transmitted and utilized without authorization.